This week Mayo Clinic in Rochester, Minn., unveiled a new, one-of-a-kind, compact 3T magnetic resonance imaging (MRI) scanner developed in collaboration with General Electric’s (GE) Global Research Center to an invitation-only audience.

In a study of stroke patients, investigators confirmed through magnetic resonance imaging (MRI) brain scans an association between the extent of disruption to the brain’s protective blood-brain barrier and the severity of bleeding following invasive stroke therapy. The results of the National Institutes of Health-funded study were published in Neurology.

A new phase 1 clinical trial from Brigham and Women's Hospital published in Radiology on June 22 evaluated the differences between pre-operative prone and supine magnetic resonance imaging (MRI) exams in 12 women undergoing lumpectomy for breast cancer.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria program for advanced diagnostic imaging. This will allow referring physicians to use SNMMI’s appropriate use criteria (AUC) to fulfill the requirements of the 2014 Protecting Access to Medicare Act (PAMA).

Developers of a new portable molecular imaging system debuted their creation at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 11-15 in San Diego. The new system combines optical imaging at the surface level and scintigraphy, which captures the physiological function of what lies beneath.

Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring LBM takes changes in individual body composition into account for better staging of disease and therapy monitoring, said researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 11-15 in San Diego.

Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 11-15 in San Diego, an investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy (PRRT) before they commit to a course of treatment.